QQQ   359.75 (-2.86%)
AAPL   141.81 (-2.45%)
MSFT   284.23 (-3.38%)
FB   340.13 (-3.80%)
GOOGL   2,712.98 (-3.84%)
TSLA   777.07 (-1.81%)
AMZN   3,312.75 (-2.73%)
NVDA   206.71 (-4.57%)
BABA   152.06 (+1.25%)
NIO   35.22 (-4.22%)
CGC   14.16 (-3.74%)
GE   105.85 (+0.47%)
MU   73.32 (-2.47%)
AMD   101.47 (-6.19%)
T   27.28 (-0.44%)
F   14.32 (+1.13%)
ACB   6.84 (+7.04%)
DIS   174.41 (-2.16%)
PFE   43.08 (-1.12%)
BA   218.75 (-2.41%)
AMC   37.19 (-5.37%)
QQQ   359.75 (-2.86%)
AAPL   141.81 (-2.45%)
MSFT   284.23 (-3.38%)
FB   340.13 (-3.80%)
GOOGL   2,712.98 (-3.84%)
TSLA   777.07 (-1.81%)
AMZN   3,312.75 (-2.73%)
NVDA   206.71 (-4.57%)
BABA   152.06 (+1.25%)
NIO   35.22 (-4.22%)
CGC   14.16 (-3.74%)
GE   105.85 (+0.47%)
MU   73.32 (-2.47%)
AMD   101.47 (-6.19%)
T   27.28 (-0.44%)
F   14.32 (+1.13%)
ACB   6.84 (+7.04%)
DIS   174.41 (-2.16%)
PFE   43.08 (-1.12%)
BA   218.75 (-2.41%)
AMC   37.19 (-5.37%)
QQQ   359.75 (-2.86%)
AAPL   141.81 (-2.45%)
MSFT   284.23 (-3.38%)
FB   340.13 (-3.80%)
GOOGL   2,712.98 (-3.84%)
TSLA   777.07 (-1.81%)
AMZN   3,312.75 (-2.73%)
NVDA   206.71 (-4.57%)
BABA   152.06 (+1.25%)
NIO   35.22 (-4.22%)
CGC   14.16 (-3.74%)
GE   105.85 (+0.47%)
MU   73.32 (-2.47%)
AMD   101.47 (-6.19%)
T   27.28 (-0.44%)
F   14.32 (+1.13%)
ACB   6.84 (+7.04%)
DIS   174.41 (-2.16%)
PFE   43.08 (-1.12%)
BA   218.75 (-2.41%)
AMC   37.19 (-5.37%)
QQQ   359.75 (-2.86%)
AAPL   141.81 (-2.45%)
MSFT   284.23 (-3.38%)
FB   340.13 (-3.80%)
GOOGL   2,712.98 (-3.84%)
TSLA   777.07 (-1.81%)
AMZN   3,312.75 (-2.73%)
NVDA   206.71 (-4.57%)
BABA   152.06 (+1.25%)
NIO   35.22 (-4.22%)
CGC   14.16 (-3.74%)
GE   105.85 (+0.47%)
MU   73.32 (-2.47%)
AMD   101.47 (-6.19%)
T   27.28 (-0.44%)
F   14.32 (+1.13%)
ACB   6.84 (+7.04%)
DIS   174.41 (-2.16%)
PFE   43.08 (-1.12%)
BA   218.75 (-2.41%)
AMC   37.19 (-5.37%)
NASDAQ:MIST

Milestone Pharmaceuticals Stock Forecast, Price & News

$5.61
-0.04 (-0.71 %)
(As of 09/28/2021 11:26 AM ET)
Add
Compare
Today's Range
$5.61
$5.61
50-Day Range
$5.34
$6.29
52-Week Range
$5.09
$9.03
Volume5 shs
Average Volume67,868 shs
Market Capitalization$167.44 million
P/E RatioN/A
Dividend YieldN/A
Beta3.89
30 days | 90 days | 365 days | Advanced Chart
Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Milestone Pharmaceuticals logo

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF), and rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MIST
CIK
N/A
Employees
28
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.80 per share

Profitability

Net Income
$-49,970,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$167.44 million
Next Earnings Date
11/12/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.94 out of 5 stars

Medical Sector

646th out of 1,353 stocks

Pharmaceutical Preparations Industry

312th out of 666 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

Is Milestone Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Milestone Pharmaceuticals stock.
View analyst ratings for Milestone Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Milestone Pharmaceuticals?

Wall Street analysts have given Milestone Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Milestone Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Milestone Pharmaceuticals
.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its quarterly earnings results on Wednesday, August, 11th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.26) by $0.28. The company earned $15 million during the quarter.
View Milestone Pharmaceuticals' earnings history
.

How has Milestone Pharmaceuticals' stock price been impacted by COVID-19?

Milestone Pharmaceuticals' stock was trading at $19.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MIST stock has decreased by 71.9% and is now trading at $5.61.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MIST?

1 Wall Street analysts have issued 12 month price objectives for Milestone Pharmaceuticals' stock. Their forecasts range from $20.00 to $20.00. On average, they expect Milestone Pharmaceuticals' share price to reach $20.00 in the next twelve months. This suggests a possible upside of 256.5% from the stock's current price.
View analysts' price targets for Milestone Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the following people:
  • Joseph G. Oliveto, President, Chief Executive Officer & Director
  • Jeff Nelson, Chief Operating Officer
  • Amit Hasija, CFO & Executive VP-Corporate Development
  • Francis Plat, Chief Medical Officer
  • Douglas Wight, Vice President-Drug Development

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

Who are Milestone Pharmaceuticals' major shareholders?

Milestone Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (6.64%), Morgan Stanley (2.97%), Morgan Stanley (2.97%), Boothbay Fund Management LLC (0.75%), Renaissance Technologies LLC (0.36%) and Susquehanna Fundamental Investments LLC (0.17%). Company insiders that own Milestone Pharmaceuticals stock include De Solidarite Des Travai Fonds, Holdings A/S Novo, Rtw Investments, Lp and Stonepine Capital, LP.
View institutional ownership trends for Milestone Pharmaceuticals
.

Which major investors are selling Milestone Pharmaceuticals stock?

MIST stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Susquehanna Fundamental Investments LLC.
View insider buying and selling activity for Milestone Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Milestone Pharmaceuticals stock?

MIST stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Morgan Stanley, Morgan Stanley, Boothbay Fund Management LLC, Citadel Advisors LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Milestone Pharmaceuticals stock in the last two years include Rtw Investments, Lp, and Stonepine Capital, LP.
View insider buying and selling activity for Milestone Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $5.61.

How much money does Milestone Pharmaceuticals make?

Milestone Pharmaceuticals has a market capitalization of $167.44 million. The company earns $-49,970,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

How many employees does Milestone Pharmaceuticals have?

Milestone Pharmaceuticals employs 28 workers across the globe.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is www.milestonepharma.com.

Where are Milestone Pharmaceuticals' headquarters?

Milestone Pharmaceuticals is headquartered at 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at (514) 336-0444 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.